Asquillies, Belgium

Celine Vanderplanck

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 29(Granted Patents)


Company Filing History:


Years Active: 2018-2024

Loading Chart...
3 patents (USPTO):Explore Patents

Title: An Insight into the Innovations of Celine Vanderplanck

Introduction: Celine Vanderplanck is a notable inventor based in Asquillies, Belgium, with an impressive portfolio of three patents. Her work primarily focuses on advancements in medical treatments, particularly targeting muscular dystrophies.

Latest Patents: Among her most notable patents is the development of agents useful in treating facioscapulohumeral muscular dystrophy. These include antisense agents and RNA interference agents that aim to reduce the expression of double homeobox 4 and/or double homeobox 4c, thereby providing breakthroughs in the treatment of this condition. The methods, uses, and additional products that employ such agents are also comprehensively described in her patent filings.

Career Highlights: Celine has contributed significantly to the academic and medical community, notably through her affiliations with Université de Mons. This institution has allowed her to collaborate closely with fellow researchers and share her innovative ideas with a larger audience.

Collaborations: Throughout her career, Celine Vanderplanck has collaborated with distinguished professionals, including Alexandra Belayew and Frederique Coppee. These partnerships have played a crucial role in advancing her research and innovations in the field of muscular dystrophy.

Conclusion: Celine Vanderplanck's contributions to the field of medical research, particularly in the area of muscular dystrophies, have established her as an influential inventor. With her innovative patents and collaborations, she continues to pave the way for significant advancements in treatment options and methodologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…